<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Genincode Plc — News on 6ix</title>
<link>https://6ix.com/company/genincode-plc</link>
<description>Latest news and press releases for Genincode Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Feb 2026 15:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/genincode-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e4e778dffbe2df127f13.webp</url>
<title>Genincode Plc</title>
<link>https://6ix.com/company/genincode-plc</link>
</image>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/genincode-plc/news/holdings-in-company-649</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/holdings-in-company-649</guid>
<pubDate>Thu, 26 Feb 2026 15:30:00 GMT</pubDate>
<description>First Equity Limited, acting as investment manager for Armstrong Investments Limited, has reduced its holding in GENinCode PLC to 4.78% of voting rights, representing 3,600,000 shares. This change, effective February 25, 2026, resulted in a decrease from a previous holding of 5.31%. The notification was made on February 26, 2026.
Disclaimer*</description>
</item>
<item>
<title>Result of GM, Director Shareholdings and TVR</title>
<link>https://6ix.com/company/genincode-plc/news/result-of-gm-director-shareholdings-and-tvr</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/result-of-gm-director-shareholdings-and-tvr</guid>
<pubDate>Mon, 09 Feb 2026 12:13:00 GMT</pubDate>
<description>GENinCode Plc announced that all resolutions concerning its placing, subscription, and retail offer were passed at a General Meeting, with resolutions to allot shares and disapply pre-emption rights receiving overwhelming support of 99.99% and 99.98% respectively. Following admission on or around February 11, 2026, the company's total issued share capital will be 753,041,137 ordinary shares, with a total of 466,159,095 new shares being admitted to trading. Several directors subscribed for new or</description>
</item>
<item>
<title>Additional Subscription</title>
<link>https://6ix.com/company/genincode-plc/news/additional-subscription-1</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/additional-subscription-1</guid>
<pubDate>Fri, 06 Feb 2026 14:39:00 GMT</pubDate>
<description>GENinCode Plc has announced an additional subscription for 58,000,000 New Ordinary Shares at 1 pence per share, raising £580,000 in gross proceeds. This additional funding, which brings the total raised in the fundraising to approximately £4.7 million, is considered materially beneficial for extending the company's cash runway as it prepares updates for its De Novo application to the FDA for its CARDIO inCode-Score test. The terms of this additional subscription are similar to the initial fundra</description>
</item>
<item>
<title>Result of Retail Offer</title>
<link>https://6ix.com/company/genincode-plc/news/result-of-retail-offer-26</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/result-of-retail-offer-26</guid>
<pubDate>Mon, 26 Jan 2026 15:00:00 GMT</pubDate>
<description>GENinCode Plc announced the successful closure of its WRAP Retail Offer, raising approximately £0.2 million through the issuance of 20,014,095 new Ordinary Shares at 1 pence per share. This brings the total gross proceeds from the overall Fundraising to approximately £4.1 million, conditional on the passing of resolutions at the General Meeting.
Disclaimer*</description>
</item>
<item>
<title>Result of Placing and Subscription</title>
<link>https://6ix.com/company/genincode-plc/news/result-of-placing-and-subscription-21</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/result-of-placing-and-subscription-21</guid>
<pubDate>Thu, 22 Jan 2026 08:24:00 GMT</pubDate>
<description>GENinCode plc has conditionally raised £3.9 million in gross proceeds through the issue of 388,145,000 New Ordinary Shares at 1 pence per share, representing a 47.4% discount to the previous closing price. Directors have subscribed for 23,000,000 shares as part of this fundraising. The company expects to announce the results of its Retail Offer on January 26, 2026, with admission of the new shares to AIM anticipated around February 11, 2026. A general meeting is scheduled for February 9, 2026, t</description>
</item>
<item>
<title>Retail Offer</title>
<link>https://6ix.com/company/genincode-plc/news/retail-offer-22</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/retail-offer-22</guid>
<pubDate>Wed, 21 Jan 2026 17:26:00 GMT</pubDate>
<description>GENinCode Plc is launching a WRAP Retail Offer to raise up to £500,000 through the issuance of up to 50,000,000 new ordinary shares at 1 pence per share. This retail offer is in addition to a proposed placing and subscription aiming to raise a minimum of £3.5 million at the same 1 pence issue price, which represents a discount of approximately 47.4% to the previous day's closing price. The proceeds from both the retail offer and the placing/subscription will be used for the same purposes, and co</description>
</item>
<item>
<title>Placing and Subscription</title>
<link>https://6ix.com/company/genincode-plc/news/placing-and-subscription-5</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/placing-and-subscription-5</guid>
<pubDate>Wed, 21 Jan 2026 17:23:00 GMT</pubDate>
<description>GENinCode PLC is undertaking a fundraising initiative to raise a minimum of £3.5 million through a placing and subscription, with an additional retail offer aiming for up to £0.5 million, all at an issue price of 1 pence per share. The funds raised will be allocated to the company's US commercialisation and scale-up program (£1.25 million), EU expansion (£0.75 million), UK expansion (£0.75 million), and general working capital and fundraising costs (£0.75 million). This fundraising is crucial fo</description>
</item>
<item>
<title>Collaboration with Sohin Genetics</title>
<link>https://6ix.com/company/genincode-plc/news/collaboration-with-sohin-genetics</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/collaboration-with-sohin-genetics</guid>
<pubDate>Wed, 17 Dec 2025 07:28:00 GMT</pubDate>
<description>GENinCode Plc has announced a commercial agreement with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® Polygenic Risk Score test, aimed at predicting and preventing coronary heart disease. This collaboration targets Mexico's significant cardiovascular disease market, estimated at USD $4.3 billion, where heart disease is the leading cause of death. Sohin Genetics will promote and market the test across its network of hospitals and clinics, leveraging GENinCode's SITAB internation</description>
</item>
<item>
<title>Collaboration with Thermo Fisher</title>
<link>https://6ix.com/company/genincode-plc/news/collaboration-with-thermo-fisher</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/collaboration-with-thermo-fisher</guid>
<pubDate>Thu, 04 Dec 2025 07:00:00 GMT</pubDate>
<description>GENinCode Plc has announced a significant collaboration with Thermo Fisher Scientific to commercialize its CARDIO inCode-Score® Polygenic Risk Score test for coronary heart disease prediction and prevention. This agreement includes manufacturing, sales, and distribution across the US and EMEA regions, with the test initially available as a Lab Developed Test before US FDA approval. The collaboration leverages Thermo Fisher's QuantStudio™ 5 Dx Real-Time PCR System and aims to address the substant</description>
</item>
<item>
<title>Approval of CARDIO inCode-score in New York state</title>
<link>https://6ix.com/company/genincode-plc/news/approval-of-cardio-incode-score-in-new-york-state</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/approval-of-cardio-incode-score-in-new-york-state</guid>
<pubDate>Wed, 03 Dec 2025 07:00:00 GMT</pubDate>
<description>GENinCode Plc has received approval from the New York State Department of Health for its CARDIO inCode-Score® Polygenic Risk Score test, enabling its inclusion in the 2025 Clinical Laboratory Fee Schedule with an average reimbursement of approximately $500.00 per test, and allowing sample collection from New York physicians for testing at their California facility. This approval signifies rigorous validation and supports the company's ongoing FDA De Novo assessment, with further data submission </description>
</item>
<item>
<title>New Study From GENinCode Shows Polygenic Risk Scores Improve the Accuracy of Cardiovascular Disease Risk Prediction</title>
<link>https://6ix.com/company/genincode-plc/news/new-study-from-genincode-shows-polygenic-risk-scores-improve-the-accuracy-of-cardiovascular-disease-risk-prediction</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/new-study-from-genincode-shows-polygenic-risk-scores-improve-the-accuracy-of-cardiovascular-disease-risk-prediction</guid>
<pubDate>Wed, 12 Nov 2025 12:15:00 GMT</pubDate>
<description>NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association ("AHA") Conference 2025, GENinCode the predictive genetics company focused on the prevention of cardiovascular disease ("CVD"), announces the presentation by ...</description>
</item>
<item>
<title>Publication of Landmark Study in JACC: Advances</title>
<link>https://6ix.com/company/genincode-plc/news/publication-of-landmark-study-in-jacc-advances</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/publication-of-landmark-study-in-jacc-advances</guid>
<pubDate>Tue, 28 Oct 2025 15:45:00 GMT</pubDate>
<description>CARDIO inCode-Score Genetic Risk Influences Cholesterol Risk and Prediction of Coronary Heart Disease IRVINE, CA / ACCESS Newswire / October 28, 2025 / GENinCode, the predictive genetics company focused on prevention of cardiovascular disease ("CVD"), ...</description>
</item>
<item>
<title>Half-year Report</title>
<link>https://6ix.com/company/genincode-plc/news/half-year-report-371</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/half-year-report-371</guid>
<pubDate>Tue, 30 Sep 2025 06:00:00 GMT</pubDate>
<description>GENinCode Plc reported a 15% increase in first-half revenues, reaching £1.60m compared to £1.39m in the first half of 2024, driven by growth in the UK, EU, and US markets. The company successfully completed a £3.7m fundraising to support expansion. The adjusted EBITDA loss, excluding unrealized forex loss, was £2.07m, slightly higher than the £2.05m loss in the prior period. Cash reserves stood at £2.44m as of June 30, 2025, a notable increase from £1.11m at the end of 2024. However, due to slow</description>
</item>
<item>
<title>NHS (UCLH) Risk of Ovarian Cancer (ROCA) launch</title>
<link>https://6ix.com/company/genincode-plc/news/nhs-uclh-risk-of-ovarian-cancer-roca-launch</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/nhs-uclh-risk-of-ovarian-cancer-roca-launch</guid>
<pubDate>Thu, 25 Sep 2025 06:00:00 GMT</pubDate>
<description>GENinCode Plc announced a collaboration with the North Central London Cancer Alliance and University College London Hospitals NHS Foundation Trust (UCLH) to launch a Risk of Ovarian Cancer Algorithm (ROCA) surveillance test service. UCLH is the first UK hospital trust to offer this service as part of its Familial Cancer Clinic, in line with new NICE guidance for women at high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene alterations. Women with BRCA1 or BRCA2 gene alterations have </description>
</item>
<item>
<title>Stmnt re Share Price Movement</title>
<link>https://6ix.com/company/genincode-plc/news/stmnt-re-share-price-movement-16</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/stmnt-re-share-price-movement-16</guid>
<pubDate>Wed, 17 Sep 2025 09:42:00 GMT</pubDate>
<description>GENinCode Plc acknowledged recent share price movement, stating they are unaware of the cause but believe the shares are undervalued. The company reaffirmed its operational position from the August 26, 2025, trading update, noting ongoing discussions with the FDA regarding De Novo and continued work to address remaining deficiencies. Collaboration discussions are in progress with a major distributor regarding potential US and EU test distribution. The company plans to update the market with its </description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/genincode-plc/news/notice-of-results-202</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/notice-of-results-202</guid>
<pubDate>Fri, 05 Sep 2025 06:00:00 GMT</pubDate>
<description>GENinCode Plc will release its unaudited interim results for the six months ended June 30, 2025, on Tuesday, September 30, 2025. An analyst briefing will be held on Thursday, October 2, 2025, at 9:30 am BST. A live investor presentation regarding these results will also occur on Thursday, October 2, 2025, at 11:00 am BST via the Investor Meet Company platform.
Disclaimer*</description>
</item>
<item>
<title>Trading update</title>
<link>https://6ix.com/company/genincode-plc/news/trading-update-310</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/trading-update-310</guid>
<pubDate>Tue, 26 Aug 2025 06:00:00 GMT</pubDate>
<description>GENinCode Plc reported a trading update for the first half of 2025, showing a 15% increase in revenues to £1.6m, compared to £1.4m for the same period in 2024. The gross profit margin remained steady at 53%. Losses for the period were £2.4m, consistent with the £2.4m loss in the first half of 2024. The company's cash position at the end of June 2025 was £2.4m, down from £2.9m at the end of June 2024. The company is progressing with FDA discussions and collaboration discussions on potential US an</description>
</item>
<item>
<title>De Novo Update – FDA Supervisory Review</title>
<link>https://6ix.com/company/genincode-plc/news/de-novo-update-fda-supervisory-review</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/de-novo-update-fda-supervisory-review</guid>
<pubDate>Mon, 07 Jul 2025 06:00:00 GMT</pubDate>
<description>De Novo Update – FDA Supervisory Review.</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/genincode-plc/news/result-of-agm-595</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/result-of-agm-595</guid>
<pubDate>Mon, 30 Jun 2025 10:42:00 GMT</pubDate>
<description>Result of AGM.</description>
</item>
<item>
<title>Final Results</title>
<link>https://6ix.com/company/genincode-plc/news/final-results-347</link>
<guid isPermaLink="true">https://6ix.com/company/genincode-plc/news/final-results-347</guid>
<pubDate>Wed, 04 Jun 2025 06:00:00 GMT</pubDate>
<description>Final Results.</description>
</item>
</channel>
</rss>